# OPTUMRX FORMULARY ANALYSIS: 2025 → 2026


Generated: 2025-12-23 20:05:46
Mode: txt_extraction
Source: optumrx_2025.pdf (60 pages)
        optumrx_2026.pdf (61 pages)

--------------------------------------------------------------------------------

# OptumRx Formulary Comparison: 2025 vs 2026

## Executive Summary

The 2026 formulary shows significant changes including **simplified tier structure** (removal of Tiers 4 and 5), **major biosimilar transitions**, **new drug additions**, and **notable exclusions**. Key themes include cost containment through generic/biosimilar preference, expanded weight management coverage, and strategic exclusions of high-cost brands.

---

## 1. Tier Structure Changes

| Element      | 2025                           | 2026        | Impact                                     |
| ------------ | ------------------------------ | ----------- | ------------------------------------------ |
| **Tier 4**   | Specialty medications          | **Removed** | Specialty drugs now in Tiers 2-3           |
| **Tier 5**   | Ultra-specialty/Gene therapies | **Removed** | Gene therapies likely carved out or Tier 3 |
| **Tier 1-3** | Standard structure             | Retained    | No change                                  |
| **Tier E**   | Excluded                       | Retained    | Expanded exclusions                        |

**Analysis**: The consolidation from 5 tiers to 3 tiers simplifies cost-sharing but may increase out-of-pocket costs for specialty medications previously in dedicated tiers.

---

## 2. Drug Additions (New to 2026 Formulary)

### High-Impact New Additions

| Drug Name             | Tier | Category                        | Restrictions | Notes                                             |
| --------------------- | ---- | ------------------------------- | ------------ | ------------------------------------------------- |
| **JOURNAVX**          | 3    | Pain (Non-opioid)               | QL           | Novel non-opioid analgesic - significant addition |
| **ZURZUVAE**          | 3    | Antidepressant (PPD)            | PA, QL       | First oral postpartum depression treatment        |
| **WEGOVY**            | 2    | Weight Management               | PA, ++, QL   | GLP-1 for chronic weight management               |
| **ZEPBOUND**          | 2    | Weight Management               | PA, ++, QL   | Tirzepatide for weight loss                       |
| **EBGLYSS**           | 2    | Dermatology (Atopic Dermatitis) | PA, SP, QL   | New IL-13 inhibitor                               |
| **NEMLUVIO**          | 2    | Dermatology                     | PA, SP, QL   | New biologic option                               |
| **WAINUA**            | 3    | CNS                             | PA, SP, QL   | New specialty CNS agent                           |
| **CABENUVA**          | 2    | HIV                             | ------------ | Long-acting injectable HIV regimen                |
| **OPZELURA**          | 2    | Dermatology                     | ST, QL       | JAK inhibitor - moved from excluded               |
| **IQIRVO**            | 3    | GI (Liver)                      | PA, SP, QL   | New for primary biliary cholangitis               |
| **LIVDELZI**          | 3    | GI (Liver)                      | PA, SP, QL   | New for primary biliary cholangitis               |
| **CAMZYOS**           | 3    | Cardiovascular                  | SP           | Hypertrophic cardiomyopathy                       |
| **VYNDAMAX/VYNDAQEL** | 3    | Cardiovascular                  | PA, SP, QL   | Transthyretin amyloidosis                         |

### New Oncology Additions

| Drug Name     | Tier | Indication             | Restrictions |
| ------------- | ---- | ---------------------- | ------------ |
| **AUGTYRO**   | 3    | Cancer                 | PA, SP       |
| **DANZITEN**  | 3    | Cancer                 | PA, SP       |
| **GAVRETO**   | 3    | RET+ cancers           | PA, SP       |
| **IMKELDI**   | 3    | Cancer                 | PA, SP       |
| **JAKAFI**    | 3    | Myelofibrosis          | PA, SP       |
| **KOSELUGO**  | 3    | Neurofibromatosis      | PA, SP       |
| **ORGOVYX**   | 3    | Prostate cancer        | PA, SP       |
| **PHESGO**    | 2    | Breast cancer          | PA, SP       |
| **RETEVMO**   | 3    | RET+ cancers           | PA, SP       |
| **ROZLYTREK** | 3    | NTRK+ cancers          | PA, SP       |
| **RUXIENCE**  | 2    | Biosimilar rituximab   | PA, SP       |
| **SCEMBLIX**  | 3    | CML                    | PA, SP       |
| **TABRECTA**  | 3    | MET+ NSCLC             | PA, SP       |
| **TRAZIMERA** | 2    | Biosimilar trastuzumab | PA, SP       |
| **TRUQAP**    | 3    | Breast cancer          | PA, SP       |
| **VITRAKVI**  | 3    | NTRK+ cancers          | PA, SP       |
| **XALKORI**   | 3    | ALK+ NSCLC             | PA, SP       |
| **ZELBORAF**  | 3    | BRAF+ melanoma         | PA, SP       |

### Other Notable Additions

| Drug Name                       | Tier | Category       | Notes                                  |
| ------------------------------- | ---- | -------------- | -------------------------------------- |
| **morphine sulfate ER**         | 1    | Pain           | Generic ER opioid added                |
| **desvenlafaxine succinate ER** | 1    | Antidepressant | Generic Pristiq                        |
| **lenalidomide**                | 1    | Oncology       | Generic Revlimid                       |
| **lubiprostone**                | 1    | GI             | Generic Amitiza                        |
| **pregabalin**                  | 1    | CNS            | Generic Lyrica                         |
| **nebivolol**                   | 1    | Cardiovascular | Generic Bystolic                       |
| **CREXONT**                     | 3    | Parkinson's    | New carbidopa-levodopa formulation     |
| **ONGENTYS**                    | 3    | Parkinson's    | COMT inhibitor                         |
| **QUVIVIQ**                     | 3    | Sleep          | Orexin receptor antagonist             |
| **VOQUEZNA**                    | 2    | GI (H. pylori) | New potassium-competitive acid blocker |
| **TALICIA**                     | 2    | GI (H. pylori) | Combination H. pylori treatment        |

---

## 3. Drug Removals/Exclusions (Covered in 2025, Excluded in 2026)

### Critical Exclusions

| Drug Name                 | 2025 Tier | Category            | Impact                               |
| ------------------------- | --------- | ------------------- | ------------------------------------ |
| **AJOVY**                 | 2         | Migraine Prevention | Major - CGRP inhibitor removed       |
| **NAMZARIC**              | 2         | Dementia            | Combination donepezil/memantine      |
| **COPAXONE 40mg**         | 2         | Multiple Sclerosis  | Brand glatiramer removed             |
| **LEVEMIR**               | 1-2       | Insulin             | Long-acting insulin removed          |
| **TRESIBA**               | 1-2       | Insulin             | Ultra-long-acting insulin removed    |
| **FREESTYLE LIBRE (all)** | 2         | CGM                 | Major CGM brand excluded             |
| **ONETOUCH (all)**        | 2         | Glucose Monitoring  | Major meter/strip brand excluded     |
| **APTIOM**                | 3         | Anticonvulsant      | Eslicarbazepine removed              |
| **VIMPAT**                | 3         | Anticonvulsant      | Brand lacosamide (generic available) |
| **IBSRELA**               | 3         | GI (IBS)            | Tenapanor removed                    |
| **TRULANCE**              | 3         | GI (Constipation)   | Plecanatide removed                  |
| **RUBRACA**               | 2         | Oncology            | PARP inhibitor removed               |
| **SPRYCEL**               | 2         | Oncology            | Dasatinib brand removed              |

### Insulin Changes Detail

| 2025 Status | 2026 Status  | Drug                     |
| ----------- | ------------ | ------------------------ |
| Covered     | **Excluded** | LEVEMIR                  |
| Covered     | **Excluded** | TRESIBA                  |
| Covered     | **Excluded** | SEMGLEE                  |
| Covered     | **Excluded** | BASAGLAR TEMPO PEN       |
| Covered     | **Excluded** | Generic insulin aspart   |
| Covered     | **Excluded** | Generic insulin glargine |

### CGM/Diabetes Supply Changes

| 2025 Status | 2026 Status  | Product                     |
| ----------- | ------------ | --------------------------- |
| Tier 2      | **Excluded** | FREESTYLE LIBRE 14 Day      |
| Tier 2      | **Excluded** | FREESTYLE LIBRE 2           |
| Tier 2      | **Excluded** | FREESTYLE LIBRE 3           |
| Tier 2      | **Excluded** | ONETOUCH meters/strips      |
| Tier 2      | Tier 2       | DEXCOM G6/G7 (retained)     |
| Tier 3      | Tier 3       | GUARDIAN sensors (retained) |

---

## 4. Tier Changes

### Drugs Moving to Lower Tiers (Cost Decrease)

| Drug          | 2025 Tier | 2026 Tier | Category    |
| ------------- | --------- | --------- | ----------- |
| **CABOMETYX** | 3-4       | 2         | Oncology    |
| **OPZELURA**  | Excluded  | 2         | Dermatology |
| **REPATHA**   | 2 (PA)    | 2 (ST)    | Cholesterol |
| **XALKORI**   | Excluded  | 3         | Oncology    |

### Drugs Moving to Higher Tiers (Cost Increase)

| Drug        | 2025 Tier   | 2026 Tier | Category       |
| ----------- | ----------- | --------- | -------------- |
| **DESCOVY** | 2           | 3         | HIV Prevention |
| **VYVANSE** | 1 (generic) | 3 (brand) | ADHD           |
| **INBRIJA** | 3-4         | Removed   | Parkinson's    |

### Restriction Changes

| Drug                | 2025 Restrictions | 2026 Restrictions | Change     |
| ------------------- | ----------------- | ----------------- | ---------- |
| **REPATHA**         | PA, QL            | ST, QL            | PA → ST    |
| **JANUMET/JANUVIA** | ST                | None              | ST removed |
| **JENTADUETO**      | ST                | None              | ST removed |
| **TRADJENTA**       | ST                | None              | ST removed |
| **VTAMA**           | PA                | ST                | PA → ST    |
| **ONEXTON**         | None              | ST                | ST added   |
| **NAPRELAN**        | PA                | None              | PA removed |

---

## 5. Biosimilar/Generic Transitions

### New Generic Availability Reflected

| Brand (2025) | Generic (2026)             | Category         |
| ------------ | -------------------------- | ---------------- |
| LYRICA       | pregabalin (Tier 1)        | Neuropathic Pain |
| BYSTOLIC     | nebivolol (Tier 1)         | Cardiovascular   |
| PRISTIQ      | desvenlafaxine ER (Tier 1) | Antidepressant   |
| REVLIMID     | lenalidomide (Tier 1)      | Oncology         |
| AMITIZA      | lubiprostone (Tier 1)      | GI               |

### New Biosimilar Additions

| Biosimilar    | Reference Product | Tier | Category |
| ------------- | ----------------- | ---- | -------- |
| **RUXIENCE**  | Rituxan           | 2    | Oncology |
| **TRAZIMERA** | Herceptin         | 2    | Oncology |

### Biosimilar Preference Maintained

| Preferred Biosimilar | Over Reference | Category     |
| -------------------- | -------------- | ------------ |
| AMJEVITA             | HUMIRA         | Rheumatology |
| HADLIMA              | HUMIRA         | Rheumatology |
| HYRIMOZ              | HUMIRA         | Rheumatology |
| CYLTEZO              | HUMIRA         | Rheumatology |
| MVASI                | Avastin        | Oncology     |
| ZIRABEV              | Avastin        | Oncology     |
| KANJINTI             | Herceptin      | Oncology     |
| INFLECTRA            | Remicade       | Rheumatology |
| AVSOLA               | Remicade       | Rheumatology |

---

## 6. Therapeutic Class Analysis

### Migraine - Significant Changes

| Change Type  | Details                                             |
| ------------ | --------------------------------------------------- |
| **Removed**  | AJOVY (fremanezumab)                                |
| **Retained** | AIMOVIG, EMGALITY, NURTEC, QULIPTA, UBRELVY         |
| **Impact**   | One fewer CGRP option; may affect patients on AJOVY |

### Multiple Sclerosis - Major Shifts

| Change Type          | Details                                                               |
| -------------------- | --------------------------------------------------------------------- |
| **Removed**          | COPAXONE 40mg (brand)                                                 |
| **Retained**         | Generic glatiramer, KESIMPTA, VUMERITY, AVONEX, BETASERON             |
| **Added Exclusions** | OCREVUS, TYSABRI, PONVORY                                             |
| **Impact**           | Significant narrowing of MS options; high-efficacy therapies excluded |

### Diabetes - CGM Consolidation

| Change Type   | Details                                                   |
| ------------- | --------------------------------------------------------- |
| **Preferred** | DEXCOM G6/G7, GUARDIAN sensors                            |
| **Excluded**  | All FREESTYLE LIBRE products, ONETOUCH, EVERSENSE         |
| **Impact**    | Major disruption for Libre users; forced switch to Dexcom |

### Diabetes - Insulin Formulary Tightening

| Change Type  | Details                                                      |
| ------------ | ------------------------------------------------------------ |
| **Removed**  | LEVEMIR, TRESIBA, generic glargine/aspart                    |
| **Retained** | LANTUS, BASAGLAR, TOUJEO, HUMALOG, NOVOLOG                   |
| **Impact**   | Reduced basal insulin options; no ultra-long-acting coverage |

### Weight Management - Expanded Coverage

| Change Type  | Details                                            |
| ------------ | -------------------------------------------------- |
| **Added**    | WEGOVY, ZEPBOUND                                   |
| **Retained** | SAXENDA, QSYMIA                                    |
| **Impact**   | Significant expansion of GLP-1 weight loss options |

### Oncology - Expanded but Selective

| Added                      | Removed/Excluded                             |
| -------------------------- | -------------------------------------------- |
| 20+ new targeted therapies | RUBRACA, SPRYCEL, IMBRUVICA (some strengths) |
| Multiple biosimilars       | AFINITOR, SUTENT, TALZENNA                   |
| Generic lenalidomide       | GLEEVEC (brand)                              |

---

## 7. Key Restriction Pattern Changes

### Prior Authorization Trends

| Trend           | Examples                                 |
| --------------- | ---------------------------------------- |
| **PA Removed**  | NAPRELAN, some diabetes combinations     |
| **PA Added**    | Multiple new specialty drugs             |
| **PA Retained** | GLP-1s, biologics, specialty medications |

### Step Therapy Changes

| Change          | Drugs Affected                          |
| --------------- | --------------------------------------- |
| **ST Removed**  | JANUMET, JANUVIA, JENTADUETO, TRADJENTA |
| **ST Added**    | ONEXTON, VTAMA, ZORYVE, REPATHA         |
| **ST Retained** | LINZESS, TRINTELLIX, BRIVIACT, XCOPRI   |

### Quantity Limit Patterns

- **Maintained** on controlled substances, specialty medications, high-cost brands
- **Added** to new specialty additions (JOURNAVX, ZURZUVAE, etc.)

---

## 8. Summary Tables

### Most Impactful Changes for Members

| Rank | Change                    | Affected Population                  | Action Required                  |
| ---- | ------------------------- | ------------------------------------ | -------------------------------- |
| 1    | FREESTYLE LIBRE exclusion | Diabetes patients on CGM             | Switch to Dexcom                 |
| 2    | LEVEMIR/TRESIBA exclusion | Basal insulin users                  | Switch to Lantus/Basaglar/Toujeo |
| 3    | AJOVY exclusion           | Migraine prevention patients         | Switch to other CGRP             |
| 4    | COPAXONE exclusion        | MS patients                          | Switch to generic glatiramer     |
| 5    | OCREVUS/TYSABRI exclusion | MS patients on high-efficacy therapy | Major coverage gap               |

### Cost-Saving Opportunities (New Generics)

| Generic           | Replaces | Estimated Savings |
| ----------------- | -------- | ----------------- |
| pregabalin        | LYRICA   | High              |
| lenalidomide      | REVLIMID | Very High         |
| nebivolol         | BYSTOLIC | Moderate          |
| desvenlafaxine ER | PRISTIQ  | Moderate          |
| lubiprostone      | AMITIZA  | Moderate          |

### New Therapeutic Options

| Drug            | Condition             | Significance                       |
| --------------- | --------------------- | ---------------------------------- |
| JOURNAVX        | Chronic Pain          | First-in-class non-opioid          |
| ZURZUVAE        | Postpartum Depression | First oral PPD treatment           |
| WEGOVY/ZEPBOUND | Obesity               | Expanded GLP-1 access              |
| CAMZYOS         | HCM                   | First approved for obstructive HCM |

---

## 9. Recommendations for Plan Sponsors

1. **Communicate CGM changes early** - Freestyle Libre exclusion will affect many members
2. **Prepare insulin transition support** - Levemir/Tresiba users need guidance
3. **Review MS population** - High-efficacy therapy exclusions may require exceptions process
4. **Leverage new generics** - Promote pregabalin, lenalidomide, nebivolol switches
5. **Monitor weight management utilization** - New GLP-1 coverage may increase costs
6. **Update PA/ST workflows** - Multiple restriction changes require system updates